PMID- 28537888
OWN - NLM
STAT- MEDLINE
DCOM- 20180423
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 29
DP  - 2017 Jul 18
TI  - High expression of miR-493-5p positively correlates with clinical prognosis of 
      non small cell lung cancer by targeting oncogene ITGB1.
PG  - 47389-47399
LID - 10.18632/oncotarget.17650 [doi]
AB  - Increasing evidence supports that microRNA (miRNA)-mediated gene regulation plays 
      a significant functional role in cancer progression. To investigate the 
      expression and clinical significance of ITGB1 in non small cell lung cancer 
      (NSCLC), the expression levels of ITGB1 in NSCLC tissues and human normal lung 
      tissues were analyzed in silico using genes microarray, KEGG pathway and 
      hierarchical clustering analysis followed by validation with quantitative RT-PCR. 
      Our results showed that ITGB1 was upregulated in NSCLC tissues when compared with 
      normal lung tissues. Survival analysis based on the qRT-PCR data established that 
      ITGB1 expression was attentively related to the prognosis of NSCLC, and patients 
      with higher ITGB1 expression had shorter overall survival (OS). Moreover, ITGB1 
      was confirmed to be a direct target of miR-493-5p. Furthermore, concomitant high 
      expression of ITGB1 and low expression of miR-493-5p correlated with a shorter 
      median OS and PFS in NSCLC patients. In conclusion, our results provide the first 
      evidence that ITGB1 is a direct target of miR-493-5p suggesting that ITGB1 and 
      miR-493-5p may have potential prognostic value and may be useful as tumor 
      biomarkers for the diagnosis of NSCLC patients.
FAU - Liang, Zhu
AU  - Liang Z
AD  - Department of Cardiothoracic Surgery, The Affiliated Hospital of Guangdong 
      Medical University, Zhanjiang 524001, China.
FAU - Kong, Rui
AU  - Kong R
AD  - Medical College of Soochow University, Soochow 215006, China.
FAU - He, Zhan
AU  - He Z
AD  - Department of Cardiothoracic Surgery, The Affiliated Hospital of Guangdong 
      Medical University, Zhanjiang 524001, China.
FAU - Lin, Li-Yao
AU  - Lin LY
AD  - Department of Cardiothoracic Surgery, The Affiliated Hospital of Guangdong 
      Medical University, Zhanjiang 524001, China.
FAU - Qin, Shan-Shan
AU  - Qin SS
AD  - Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, Shanghai 200072, China.
FAU - Chen, Chun-Yuan
AU  - Chen CY
AD  - Department of Cardiothoracic Surgery, The Affiliated Hospital of Guangdong 
      Medical University, Zhanjiang 524001, China.
FAU - Xie, Zhan-Qiang
AU  - Xie ZQ
AD  - Department of Cardiothoracic Surgery, The Affiliated Hospital of Guangdong 
      Medical University, Zhanjiang 524001, China.
FAU - Yu, Fei
AU  - Yu F
AD  - Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, Shanghai 200072, China.
FAU - Sun, Guo-Qian
AU  - Sun GQ
AD  - Department of Cardiothoracic Surgery, The Affiliated Hospital of Guangdong 
      Medical University, Zhanjiang 524001, China.
FAU - Li, Chun-Guang
AU  - Li CG
AD  - Department of Thoracic Surgery, Changhai Hospital of Second Military Medical 
      University, Shanghai 200433, China.
FAU - Fu, Da
AU  - Fu D
AD  - Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, Shanghai 200072, China.
FAU - Jiang, Geng-Xi
AU  - Jiang GX
AD  - Department of Thoracic Surgery, Changhai Hospital of Second Military Medical 
      University, Shanghai 200433, China.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Cardiothoracic Surgery, The Affiliated Hospital of Guangdong 
      Medical University, Zhanjiang 524001, China.
FAU - Ma, Yu-Shui
AU  - Ma YS
AD  - Department of Nuclear Medicine, Shanghai Tenth People's Hospital, Tongji 
      University School of Medicine, Shanghai 200072, China.
AD  - Shanghai Engineering Research Center of Molecular Therapeutics and New Drug 
      Development, College of Chemistry and Molecular Engineering, East China Normal 
      University, Shanghai 200062, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Integrin beta1)
RN  - 0 (MIRN493 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/*genetics/*mortality/pathology
MH  - Computational Biology/methods
MH  - Databases, Genetic
MH  - Disease Progression
MH  - Female
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation, Neoplastic
MH  - Gene Ontology
MH  - Humans
MH  - Integrin beta1/*genetics
MH  - Lung Neoplasms/*genetics/*mortality/pathology
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Molecular Sequence Annotation
MH  - Neoplasm Staging
MH  - Prognosis
MH  - *RNA Interference
MH  - Reproducibility of Results
PMC - PMC5564573
OTO - NOTNLM
OT  - ITGB1
OT  - biomarker
OT  - miR-493-5p
OT  - survival
OT  - target
COIS- CONFLICTS OF INTEREST The authors declare no potential conflicts of interest.
EDAT- 2017/05/26 06:00
MHDA- 2018/04/24 06:00
PMCR- 2017/07/18
CRDT- 2017/05/25 06:00
PHST- 2017/02/17 00:00 [received]
PHST- 2017/04/19 00:00 [accepted]
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2018/04/24 06:00 [medline]
PHST- 2017/05/25 06:00 [entrez]
PHST- 2017/07/18 00:00 [pmc-release]
AID - 17650 [pii]
AID - 10.18632/oncotarget.17650 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jul 18;8(29):47389-47399. doi: 10.18632/oncotarget.17650.